6 Results for "

CD28-B7

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "CD28-B7" in MCE Product Catalog:

Cat. No.: HY-P1698
CAS No.: 1447799-33-8
Synonyms: AB-103
Target:  

Bacterial CD28

Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs) .
loading...
    loading...
Cat. No.: HY-175780
CAS No.: 1465291-19-3
Research Areas:  

Cancer

CD28-IN-1 (Compound 19MS-5) is a CD28 inhibitor with a KD of 12.48  μM. CD28-IN-1 has a superior binding capacity to CD28 and potently inhibits CD28-B7 interactions. CD28-IN-1 inhibits CD28-driven immune activation and suppresses cytokine (IFN-γ, IL-2 and TNF-α) production in primary human T cells co-cultured with tumor spheroids and human epithelial tissues. CD28-IN-1 can be used for tumor immunity research .
loading...
    loading...
Cat. No.: HY-P1698B
Synonyms: AB-103 TFA
Target:  

Bacterial CD28

Reltecimod (AB-103) TFA is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod TFA has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod TFA modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod TFA can be used to research necrotizing soft-tissue infections (NSTIs) .
loading...
    loading...
Cat. No.: HY-179648
CAS No.: 1240857-57-1
Target:  

CD28

Research Areas:  

Inflammation/Immunology Cancer

CD28-IN-2 is a selective CD28-B7 interaction (IC50: 22.4 μM) inhibitor that binds directly to CD28, with a Kd value of 24.1 μM. CD28-IN-2 inhibits CD28-driven immune activation and blocks T cell costimulation. CD28-IN-2 can be used for the study of antitumor immunity and immune-related disorders .
loading...
    loading...
Cat. No.: HY-181507
CAS No.: 850550-70-8
Research Areas:  

Cancer

CD28-IN-3 is a CD28 inhibitor with an IC50 of 7.80 μM and a Kd of 52.45 μM. CD28-IN-3 selectively blocks the CD28-B7 interaction, thereby inhibiting CD28-mediated costimulation. CD28-IN-3 suppresses the production of proinflammatory cytokines IFN-γ, IL-2 and TNF-α. CD28-IN-3 can be used in the research of checkpoint-resistant cancers .
loading...
    loading...
Cat. No.: HY-P1698A
CAS No.: 1943755-99-4
Synonyms: AB-103 sodium
Target:  

Bacterial CD28

Reltecimod sodium (AB-103 sodium) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod sodium has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod sodium modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod sodium can be used to research necrotizing soft-tissue infections (NSTIs) .
loading...
    loading...